Benralizumab resulted in a 45-51% reduction in exacerbation rates compared to placebo (reduction from 3.0 to 0.73 per year for treatment every 4 weeks; ...

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Benralizumab, an anti–interleukin-5-receptor antibody, was evaluated in a 24-week study involving 12 patients with chronic spontaneous urticaria. The disease was assessed on the basis of ...

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet ...

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial, The Lancet Respiratory Medicine.

Gastroenterology > General Gastroenterology Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis — But there was no significant difference in symptom relief compared with placebo ...

The benralizumab group not only had fewer symptoms, but it also took longer for them to suffer an event so severe they had to either see a doctor or go to the hospital, researchers found.

Benralizumab is an anti-eosinophil monoclonal antibody that induces direct, rapid and near-complete depletion of eosinophils, with an onset of action within 24 hours as confirmed in early phase I ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Find out how to take Benralizumab(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).